CTBO (Cantabio Pharmaceuticals) YoY EBITDA Growth: 194.03% (As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals YoY EBITDA Growth?

Cantabio Pharmaceuticals CTBO YoY EBITDA Growth is 194.03% as of Dec. 2018.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cantabio Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2018 was 194.03%.

Cantabio Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2018 was $40.59.

Cantabio Pharmaceuticals YoY EBITDA Growth Related Terms

Cantabio Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals YoY EBITDA Growth Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
YoY EBITDA Growth
Get a 7-Day Free Trial -93.33 42.53 -1,777.50 -14.19 -8.21

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.65 -31.10 80.71 49.71 194.03

Cantabio Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cantabio Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2018 is calculated as:

YoY EBITDA Growth (A: Mar. 2018 )
=(EBITDA per Share (A: Mar. 2018 )-EBITDA per Share (A: Mar. 2017 ))/ | EBITDA per Share (A: Mar. 2017 ) |
=(-232--214.4)/ | -214.4 |
=-8.21 %

Cantabio Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2018 is calculated as:

YoY EBITDA Growth (Q: Dec. 2018 )
=(EBITDA per Share (Q: Dec. 2018 )-EBITDA per Share (Q: Dec. 2017 )) / | EBITDA per Share (Q: Dec. 2017 )) |
=(40.588--43.167)/ | -43.167 |
=194.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 194.03% mean?
Cantabio Pharmaceuticals (CTBO) has a YoY EBITDA Growth of 194.03% as of Dec. 2018. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' YoY EBITDA Growth too high?
Cantabio Pharmaceuticals' current YoY EBITDA Growth is 194.03%.
How does Cantabio Pharmaceuticals' YoY EBITDA Growth compare to TNTY and ETNI?
Cantabio Pharmaceuticals' YoY EBITDA Growth of 194.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current YoY EBITDA Growth is 194.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current YoY EBITDA Growth of 194.03%. The current YoY EBITDA Growth is 194.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current YoY EBITDA Growth is 194.03% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.